Dr. Delaney joins Coeptis after securing
exclusive rights from Deverra Therapeutics for its allogeneic
immuno-oncology platform and clinical stage programs
WEXFORD,
Pa., Aug. 30, 2023 /PRNewswire/ -- Coeptis
Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the
Company"), a biopharmaceutical company developing innovative cell
therapy platforms for cancer, announced that Colleen Delaney, MD, MSc, has been appointed
Chief Scientific and Medical Officer of Coeptis following the
completion of an exclusive rights agreement with Deverra
Therapeutics for its allogeneic immuno-oncology platform and
clinical stage programs.
Dr. Delaney brings to Coeptis more than two decades of
experience as a trained oncologist and stem cell transplant
physician scientist with expertise in the translation of scientific
discovery to clinical practice, including all aspects of cell
therapy product development, from initial discovery to pre-clinical
and Investigational New Drug (IND)-enabling studies, manufacturing,
global regulatory experience, and clinical trial design. She has
served on a multiple cell and gene therapy focused federal advisory
committees and as a Director for several nonprofit
associations.
In addition to her industry experience, Dr. Delaney is a
Clinical Professor at the University of
Washington, Division of Pediatric Hematology/Oncology, and
is an Affiliate and former Professor at the Fred Hutch, where she
also held the Madeline Dabney Adams Endowed Chair in AML research.
She earned her MSc from Oxford
University and her MD from Harvard
Medical School.
"Dr. Delaney is a visionary researcher who has dedicated her
life to patients as a practicing physician and through her career
as a global leader advancing all aspects of cell therapy product
development," said Dave Mehalick,
President and CEO of Coeptis Therapeutics. "Colleen's work with
Deverra and the impressive pipeline of technologies she developed
demonstrate her ingenuity and scientific acumen. Coeptis is excited
to benefit from Colleen's unrivaled expertise and industry
knowledge as we seek to maximize the combined technologies of
Coeptis and Deverra to bring to the market impactful off-the-shelf
cellular immunotherapies for on-demand treatment of patients with
cancer and infectious diseases."
"I'm thrilled to join Coeptis as we build an industry leading
pipeline of cell therapy technologies for a variety of cancers,"
said Dr. Delaney. "Our team at Deverra laid a strong scientific
foundation, and I'm confident that together with the novel and
creative thinking at Coeptis, we can make substantial strides in
delivering new treatments to patients and bring value to
shareholders."
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its
subsidiaries including Coeptis Therapeutics,
Inc. and Coeptis Pharmaceuticals,
Inc., (collectively "Coeptis"), is a biopharmaceutical
company developing innovative cell therapy platforms for cancer
that have the potential to disrupt conventional treatment paradigms
and improve patient outcomes. Coeptis' product portfolio and rights
are highlighted by assets licensed from Deverra Therapeutics,
including an allogeneic cellular immunotherapy platform and DVX201,
a clinical-stage, unmodified natural killer cell therapy
technology. Additionally, Coeptis is developing a universal,
multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and the
GEAR™ cell therapy and companion diagnostic
platforms, which Coeptis is developing with VyGen-Bio and
leading medical researchers at the Karolinska Institutet.
Coeptis' business model is designed around maximizing the value of
its current product portfolio and rights through in-license
agreements, out-license agreements and co-development
relationships, as well as entering into strategic partnerships to
expand its product rights and offerings, specifically those
targeting cancer. The Company is headquartered in Wexford, PA.
For more information on Coeptis
visit https://coeptistx.com/.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in
connection therewith contain or may contain "forward-looking
statements" (as defined in Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended). Forward-looking statements include statements
concerning our plans, objectives, goals, strategies, future events
or performance, and underlying assumptions, and other statements
that are other than statements of historical facts. When we use
words such as "may," "will," "intend," "should," "believe,"
"expect," "anticipate," "project," "estimate" or similar
expressions that do not relate solely to historical matters, we are
making forward-looking statements. Forward-looking statements are
not a guarantee of future performance and involve significant risks
and uncertainties that may cause the actual results to differ
materially and perhaps substantially from our expectations
discussed in the forward-looking statements. Factors that may cause
such differences include but are not limited to: (1) the inability
to maintain the listing of the Company's securities on the Nasdaq
Capital Market; (2) the risk that the integration of the Deverra
licensed assets will disrupt current plans and operations of the
Company; (3) the inability to recognize the anticipated benefits of
the newly-licensed assets, which may be affected by, among other
things, competition, the ability of the Company to grow and manage
growth economically and hire and retain key employees; (4) the
risks that the Company's products in development or the
newly-licensed assets fail clinical trials or are not approved by
the U.S. Food and Drug Administration or other applicable
regulatory authorities; (5) costs related to integrating the
newly-licensed Deverra assets and pursuing the contemplated asset
development paths; (6) changes in applicable laws or regulations;
(7) the possibility that the Company may be adversely affected by
other economic, business, and/or competitive factors; and (8) the
impact of the global COVID-19 pandemic on any of the foregoing
risks and other risks and uncertainties identified in the Company's
filings with the Securities and Exchange Commission (the "SEC").
The foregoing list of factors is not exclusive. All forward-looking
statements are subject to significant uncertainties and risks
including, but not limited, to those risks contained or to be
contained in reports and other filings filed by the Company with
the SEC. For these reasons, among others, investors are cautioned
not to place undue reliance upon any forward-looking statements in
this press release. Additional factors are discussed in the
Company's filings made or to be made with the SEC, which are
available for review at www.sec.gov. We undertake no obligation to
publicly revise these forward-looking statements to reflect events
or circumstances that arise after the date hereof unless required
by applicable laws, regulations, or rules.
CONTACTS
Coeptis Therapeutics, Inc.
Andy Galy, Sr. VP of Communications
andy.galy@coeptistx.com
Tiberend Strategic Advisors, Inc.
Investors
Daniel
Kontoh-Boateng
dboateng@tiberend.com
Media
David
Schemelia
dschemelia@tiberend.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-appoints-colleen-delaney-md-as-chief-scientific-and-medical-officer-301914013.html
SOURCE Coeptis Therapeutics